Dendritic cell (DC) vaccines induce specific immune responses that can selectively
eliminate target cells. In recent years, many studies have been conducted to explore DC …

Over the last decade, the active role of the microenvironment in the pathogenesis of B cell
lymphomas has been recognized, delivering signals that favor clonal expansion and drug …

Chimeric antigen receptor (CAR) T cells provide great efficacy in B cell malignancies.
However, improved CAR T cell therapies are still needed. Here, we engineered tumor …

Nanotechnology has the potential to increase the selectivity and potency of chemical,
physical, and biological approaches for eliciting cancer cell death while minimizing …

Oncolytic viruses have had a tumultuous course, from the initial anecdotal reports of patients
having antineoplastic effects after natural viral infections a century ago to the development of …

The management of chronic lymphocytic leukemia (CLL) is undergoing profound changes.
Several new drugs have been approved for CLL treatment (fludarabine, bendamustine, and …

Disease Overview: Chronic lymphocytic leukemia (CLL) is the commonest leukemia in
western countries. The disease typically occurs in elderly patients and has a highly variable …

Human gamma delta T cells have extraordinary properties including the capacity for tumor
cell killing. The major gamma delta T cell subset in human beings is designated Vγ9Vδ2 and …

Oncolytic viruses are natural or genetically modified viral species that selectively infect and
kill neoplastic cells. Such an innate or exogenously conferred specificity has generated …

CD40 agonists bind the CD40 molecule on antigen-presenting cells and activate them to
prime tumor-specific CD8+ T cell responses. Here, we study the antitumor activity and …